This company has been acquired
PRTK Stock Overview
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Paratek Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.23 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$1.29 |
| Beta | 1.7 |
| 1 Month Change | 2.29% |
| 3 Month Change | 0.91% |
| 1 Year Change | -2.62% |
| 3 Year Change | -60.95% |
| 5 Year Change | -77.01% |
| Change since IPO | -86.06% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Shareholder Returns
| PRTK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.3% | -2.4% | -1.7% |
| 1Y | -2.6% | 3.7% | 12.1% |
Return vs Industry: PRTK underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Return vs Market: PRTK underperformed the US Market which returned 13.8% over the past year.
Price Volatility
| PRTK volatility | |
|---|---|
| PRTK Average Weekly Movement | 1.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PRTK has not had significant price volatility in the past 3 months.
Volatility Over Time: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
Paratek Pharmaceuticals, Inc. Fundamentals Summary
| PRTK fundamental statistics | |
|---|---|
| Market cap | US$127.83m |
| Earnings (TTM) | -US$62.73m |
| Revenue (TTM) | US$177.00m |
0.7x
P/S Ratio-2.0x
P/E RatioIs PRTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTK income statement (TTM) | |
|---|---|
| Revenue | US$177.00m |
| Cost of Revenue | US$64.13m |
| Gross Profit | US$112.87m |
| Other Expenses | US$175.60m |
| Earnings | -US$62.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 63.77% |
| Net Profit Margin | -35.44% |
| Debt/Equity Ratio | -128.3% |
How did PRTK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/22 01:32 |
| End of Day Share Price | 2023/09/20 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Paratek Pharmaceuticals, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Timothy Chiang | BTIG |